by Admin | May 17, 2023 | Portfolio News
Previously announced $85 million financing extended by $50 million BOSTON, May 16, 2023 – Ensoma, a genomic medicines company developing one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the...
by Admin | Mar 7, 2023 | Portfolio News
SAN DIEGO, March 6, 2023 /PRNewswire/ — Phanes Therapeutics, Inc., a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that it has entered into a research collaboration with Xyphos...
by Admin | Dec 5, 2022 | Portfolio News
近日，据悉三叶草生物（香港联交所股票代码：02197）旗下领先的新冠疫苗SCB-2019（CpG1018/铝佐剂）经国家有关部门评估后被纳入紧急使用。 三叶草生物开发了SCB-2019抗原——一种基于SARS-CoV-2（新冠病毒）原始毒株S蛋白的稳定的三聚体结构融合蛋白（S-三聚体™）。其新冠疫苗SCB-2019（CpG1018/铝佐剂）是由SCB-2019抗原联合两种佐剂，即Dynavax的CpG 1018佐剂及氢氧化铝（铝佐剂）组成。 据三叶草生物全球五个国家入组超过3万名受试者的“SPECTRA” II/III...
by Admin | Nov 30, 2022 | Portfolio News
Funding will support development of lead assets and enhance target discovery and platform development CAMBRIDGE, Mass., Nov. 29, 2022 /PRNewswire/ — Rgenta Therapeutics Inc. announced today that it closed a $52 million Series A round led...
by Admin | Nov 3, 2022 | Portfolio News
Boston/Shanghai/November 3rd, 2022 — Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence a Phase I trial of its glucagon-like peptide 1 receptor agonist (GLP-1 RA) ECC5004...
by Admin | Oct 14, 2022 | Portfolio News
美国圣地亚哥，中国上海、广东松山湖 2022年10月14日，专注于肿瘤领域的临床阶段生物技术公司凡恩世公司（Phanes Therapeutics）今天宣布，其DLL3/CD47双特异性抗体（双抗）PT217获得美国食品药品监督管理局（FDA）临床试验批准，将在小细胞肺癌（SCLC）和其他神经内分泌癌患者中开展I期临床试验。PT217近期也已获FDA孤儿药资格认定。...
by Admin | Sep 8, 2022 | Delos News
We would like to congratulate Dr. Eric Huang, Operating Partner at Delos Capital for being presented with the prestigious 2022 Warren Alpert Foundation Prize! Each year the recipient(s) of the Warren Alpert Foundation Prize are recognized at a scientific symposium...
by Admin | Aug 30, 2022 | Portfolio News
— 12 to 61-fold increase in neutralizing antibodies against BA.5 among participants receiving SCB-2019 (CpG 1018/Alum) as a homologous third dose or with a history of prior SARS-CoV-2 infection — — BA.5 neutralizing antibody levels were approximately...
by Admin | Aug 29, 2022 | Portfolio News
SAN DIEGO, Aug. 23, 2022 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in oncology, announced today that the first patient has been dosed in the phase 1 clinical study...
by Admin | Aug 29, 2022 | Portfolio News
— SCB-2019 (CpG 1018/Alum) elicited approximately 2-fold higher neutralizing antibody titers in adolescents (aged 12 to 17 years) compared to young adults (aged 18 to 25 years) — — Favorable tolerability and safety profile in adolescents,...
